Clorotepine mesylate

• CAT Number: I024991
• CAS Number: 42505-79-3
• Molecular Formula: C20H25ClN2O3S2
• Molecular Weight: 441.00
• Purity: 98%
• Synonyms: Clorotepine mesylate; Clorotepin methanesulfonate
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 1-(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)-4-methylpiperazine;methanesulfonic acid
• InChI: InChI=1S/C19H21ClN2S.CH4O3S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19;1-5(2,3)4/h2-7,13,17H,8-12H2,1H3;1H3,(H,2,3,4)
• InChIKey: XQRUOHZMMIUQSB-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl.CS(=O)(=O)O

Clorotepine mesylate（Cat No.:I024991）is a synthetic compound used primarily as a central nervous system (CNS) agent with antipsychotic properties. It acts as a dopamine receptor antagonist, particularly at the D2 receptor, and may also have effects on other neurotransmitter systems, including serotonin and norepinephrine. This makes it useful for managing disorders like schizophrenia and other psychotic conditions. Clorotepine mesylate is thought to help reduce symptoms such as delusions, hallucinations, and cognitive impairment. While it shows promise in clinical use, further studies are needed to fully understand its safety profile and long-term effectiveness.

Reference

1: Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. PMID: 7908055.
2: Viswanathan G, Yadav S, Raghunand TR. Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00425-17. doi: 10.1128/AAC.00425-17. PMID: 28438925; PMCID: PMC5487644.
3: Risgaard R, Ettrup A, Balle T, Dyssegaard A, Hansen HD, Lehel S, Madsen J, Pedersen H, Püschl A, Badolo L, Bang-Andersen B, Knudsen GM, Kristensen JL. Radiolabelling and PET brain imaging of the α₁-adrenoceptor antagonist Lu AE43936. Nucl Med Biol. 2013 Jan;40(1):135-40. doi: 10.1016/j.nucmedbio.2012.09.010. Epub 2012 Nov 17. PMID: 23165140.
4: Nisa S, Blokpoel MC, Robertson BD, Tyndall JD, Lun S, Bishai WR, O’Toole R. Targeting the chromosome partitioning protein ParA in tuberculosis drug discovery. J Antimicrob Chemother. 2010 Nov;65(11):2347-58. doi: 10.1093/jac/dkq311. Epub 2010 Sep 1. PMID: 20810423; PMCID: PMC2980951.
5: Kristensen JL, Püschl A, Jensen M, Risgaard R, Christoffersen CT, Bang- Andersen B, Balle T. Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors. J Med Chem. 2010 Oct 14;53(19):7021-34. doi: 10.1021/jm100652h. PMID: 20857909.
6: Tehan BG, Lloyd EJ, Wong MG. Molecular field analysis of clozapine analogs in the development of a pharmacophore model of antipsychotic drug action. J Mol Graph Model. 2001;19(5):417-26, 468. doi: 10.1016/s1093-3263(00)00101-7. PMID: 11552690.
7: Zapletálek M, Zbytovský J, Kindernayová H. Clinical and experimental study of oxyprothepine. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1980;23(4):487-90. PMID: 6111116.
8: Metysová J, Metys J, Dlabac A, Kazdová E, Valchár M. Pharmacological properties of a potent neuroleptic drug octoclothepin. Acta Biol Med Ger. 1980;39(6):723-40. PMID: 6893891.
9: Polák L, Molcan J. Clonidine in hyperkinetic children. Act Nerv Super (Praha). 1990 Mar;32(1):66-7. PMID: 1973018.
10: Bøgesø KP, Liljefors T, Arnt J, Hyttel J, Pedersen H. Octoclothepin enantiomers. A reinvestigation of their biochemical and pharmacological activity in relation to a new receptor-interaction model for dopamine D-2 receptor antagonists. J Med Chem. 1991 Jul;34(7):2023-30. doi: 10.1021/jm00111a015. PMID: 1676758.